ERBB2 and non-Hodgkin lymphoma: We have shown that ATC from patients can be armed with anti-CD3 × anti-HER2 BiAb to treat metastatic breast (5) and metastatic prostate (6) cancers, anti-CD3 × anti-CD20 BiAb to treat non-Hodgkin's lymphoma (7, 14) and MM (10), and anti-CD3 × anti-GD2 BiAb to treat neuroblastoma and osteosarcoma (15).